Viridian Therapeutics presents 54 percent trial data for VRDN stock

Published on 10/20/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elegrobart reached 54 percent responders versus 18 percent placebo on October 15, 2026. VRDN stock costs EUR 18.50 on October 20, 2026.

Elegrobart trial and earnings

Elegrobart produced 54 percent responders versus 18 percent for placebo on October 15, 2026.
The REVEAL-1 trial enrolled 132 adults with active thyroid eye disease.
Viridian Therapeutics stock trades at EUR 18.50 at 1:45 p.m. CEST at Lang & Schwarz on October 20, 2026.

VRDN, US92790C1045, Illustration mit AI erstellt.

Viridian Therapeutics (US92790C1045) was trading at EUR 18.50 at Lang & Schwarz on October 20, 2026 at 1:45 p.m. CEST. On October 15, 2026, the company presented phase 3 REVEAL-1 data showing a 54 percent proptosis responder rate for Q4W elegrobart versus 18 percent for placebo, according to Ophthalmology Management.

Three milestones shape the pipeline

The chronology shows how the investment case has moved from analyst expectations toward clinical execution. On June 29, 2026, Wells Fargo raised its target from USD 20.00 to USD 31.00 and upgraded the rating from equal weight to overweight, according to MarketBeat. On August 7, 2026, Truist Financial lifted its target from USD 38.00 to USD 39.00 while keeping a buy rating, the same MarketBeat report said. The current event came on October 15, 2026, when REVEAL-1 showed the 54 percent versus 18 percent result.

What does the trial mean for execution?

The clinical signal is commercially relevant because the trial tested subcutaneous dosing in 132 adults with moderate-to-severe active thyroid eye disease. The every-eight-week arm produced a 63 percent responder rate versus 18 percent for placebo, while mean proptosis reduction reached 2.50 millimeters versus 0.81 millimeters, according to Ophthalmology Management. Safety remains part of the commercial calculation: muscle spasms occurred in 41 percent of Q4W patients and 36 percent of Q8W patients, versus 7 percent with placebo.

Viridian's second-quarter 2026 revenue was USD 0.28 million, while adjusted earnings per share were a loss of USD 1.05 versus a consensus loss of USD 1.03, according to MarketBeat. That contrast leaves clinical differentiation and the path toward commercialization as the central valuation questions.

Next reporting date is November 4

The next substantiated date is November 4, 2026, when Viridian is scheduled to report results for the September 2026 period, according to MetaCap. The report should add operating detail to the trial readout and provide the next quantified view of the company's cash use.

VRDN stock and clinical milestones

Viridian Therapeutics is valued at USD 2.4 billion based on the October 19, 2026 market capitalization. Its primary listing is on Nasdaq, and the stock's 52-week range was USD 13.18 to USD 34.29 as of October 16, 2026. The company develops antibody therapies for autoimmune and rare diseases, with thyroid eye disease as its immediate focus.

The stock was trading at EUR 18.50 at Lang & Schwarz on October 20, 2026 at 1:45 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Viridian Therapeutics stock.